A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Recruiting · NCT07487896 · Registry updated 2026-07-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | Advanced Esophageal Squamous Cell Carcinoma | Recruiting | Phase 3 | 2026-07-16 | NCT07487896 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| MediLink Therapeutics (Suzhou) Co., Ltd. | 24 |
81 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| 101 | Jinan | China | 1 |
| 102 | Anyang | China | 1 |
| 103 | Zhengzhou | China | 1 |
| 104 | Zhengzhou | China | 1 |
| 105 | Luoyang | China | 1 |
| 106 | Shanghai | China | 1 |
| 107 | Nanjing | China | 1 |
| 108 | Hangzhou | China | 1 |
| 109 | Hangzhou | China | 1 |
| 110 | Fuzhou | China | 1 |
| 111 | Chengdu | China | 1 |
| 112 | Nanning | China | 1 |
| 113 | Wuhan | China | 1 |
| 114 | Wuhan | China | 1 |
| 115 | Kunming | China | 1 |
| 116 | Chengdu | China | 1 |
| 117 | Nanchang | China | 1 |
| 118 | Chengdu | China | 1 |
| 119 | Chongqing | China | 1 |
| 120 | Chongqing | China | 1 |
| 121 | Nanchang | China | 1 |
| 122 | Harbin | China | 1 |
| 123 | Taiyuan | China | 1 |
| 124 | Tianjin | China | 1 |
| 125 | Changchun | China | 1 |